{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:26:47Z","timestamp":1783114007087,"version":"3.54.6"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Peripheral ulcerative keratitis (PUK) is a severe corneal condition associated with uncontrolled RA. Tocilizumab (TCZ) is used to control RA, however, episodes of paradoxical ocular inflammation have been reported in TCZ-treated patients. We report a case series of PUK in TCZ-treated RA patients with ophthalmological and systemic findings and discuss the potential underlying mechanisms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Four patients (six eyes), 47\u201362\u2009years of age, were included. At the onset of PUK, the median duration of RA was 13\u2009years [interquartile range (IQR) 3\u201313] and the median treatment with TCZ was 9\u2009months (IQR 3\u201314). Two patients had active disease [28-joint DAS (DAS28) &amp;gt;3.2] and the disease was controlled in two patients (DAS28 \u22643.2).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>TCZ was initially replaced by another immunomodulatory treatment in all patients and later reintroduced in two patients without PUK recurrence. Corneal inflammation was controlled in all cases with local and systemic treatments, with severe visual loss in one eye.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>PUK may occur in patients with long-standing RA after a switch to TCZ and can be interpreted, depending on the context, as insufficient efficacy or a paradoxical manifestation. These cases highlight the urgent need for reliable biomarkers of the efficacy and paradoxical reactions of biologics.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab093","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T21:31:01Z","timestamp":1611869461000},"page":"5413-5418","source":"Crossref","is-referenced-by-count":15,"title":["Peripheral ulcerative keratitis in rheumatoid arthritis patients taking tocilizumab: paradoxical manifestation or insufficient efficacy?"],"prefix":"10.1093","volume":"60","author":[{"given":"Florian","family":"Cohen","sequence":"first","affiliation":[{"name":"Service d\u2019Ophtalmologie, Assistance Publique \u2013 H\u00f4pitaux de Paris, Universit\u00e9 Paris-Saclay, Centre de R\u00e9f\u00e9rence Maladies Rares en Ophtalmologie, OPHTARA, Le Kremlin-Bic\u00eatre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Ernest","family":"Gabison","sequence":"additional","affiliation":[{"name":"Service d'Ophtalmologie, Assistance Publique \u2013 H\u00f4pitaux de Paris, H\u00f4pital Bichat et Fondation Ophtalmologique Rothschild, Centre de R\u00e9f\u00e9rence Maladies Rares en Ophtalmologie, OPHTARA, Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"St\u00e9phan","sequence":"additional","affiliation":[{"name":"Service d'Ophtalmologie, Assistance Publique \u2013 H\u00f4pitaux de Paris, H\u00f4pital Bichat et Fondation Ophtalmologique Rothschild, Centre de R\u00e9f\u00e9rence Maladies Rares en Ophtalmologie, OPHTARA, Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakiba","family":"Belkhir","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Assistance Publique \u2013 H\u00f4pitaux de Paris, H\u00f4pitaux universitaires Paris-Saclay\u2014H\u00f4pital Bic\u00eatre, Le Kremlin Bic\u00eatre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetane","family":"Nocturne","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Assistance Publique \u2013 H\u00f4pitaux de Paris, H\u00f4pitaux universitaires Paris-Saclay\u2014H\u00f4pital Bic\u00eatre, Le Kremlin Bic\u00eatre"},{"name":"Department of Immunology of Viral and Auto-Immune Disease, UMR1184, CEA, Fontenay-aux-Roses, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laurence","family":"Best","sequence":"additional","affiliation":[{"name":"Service d\u2019Ophtalmologie, Assistance Publique \u2013 H\u00f4pitaux de Paris, Universit\u00e9 Paris-Saclay, Centre de R\u00e9f\u00e9rence Maladies Rares en Ophtalmologie, OPHTARA, Le Kremlin-Bic\u00eatre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Haigh","sequence":"additional","affiliation":[{"name":"Department of Immunology of Viral and Auto-Immune Disease, UMR1184, CEA, Fontenay-aux-Roses, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Barreau","sequence":"additional","affiliation":[{"name":"Service d\u2019Ophtalmologie, Assistance Publique \u2013 H\u00f4pitaux de Paris, Universit\u00e9 Paris-Saclay, Centre de R\u00e9f\u00e9rence Maladies Rares en Ophtalmologie, OPHTARA, Le Kremlin-Bic\u00eatre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Labetoulle","sequence":"additional","affiliation":[{"name":"Service d\u2019Ophtalmologie, Assistance Publique \u2013 H\u00f4pitaux de Paris, Universit\u00e9 Paris-Saclay, Centre de R\u00e9f\u00e9rence Maladies Rares en Ophtalmologie, OPHTARA, Le Kremlin-Bic\u00eatre"},{"name":"Department of Immunology of Viral and Auto-Immune Disease, UMR1184, CEA, Fontenay-aux-Roses, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphaele","family":"Seror","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Assistance Publique \u2013 H\u00f4pitaux de Paris, H\u00f4pitaux universitaires Paris-Saclay\u2014H\u00f4pital Bic\u00eatre, Le Kremlin Bic\u00eatre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Rousseau","sequence":"additional","affiliation":[{"name":"Service d\u2019Ophtalmologie, Assistance Publique \u2013 H\u00f4pitaux de Paris, Universit\u00e9 Paris-Saclay, Centre de R\u00e9f\u00e9rence Maladies Rares en Ophtalmologie, OPHTARA, Le Kremlin-Bic\u00eatre"},{"name":"Department of Immunology of Viral and Auto-Immune Disease, UMR1184, CEA, Fontenay-aux-Roses, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"key":"2021110402580715800_keab093-B1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrrheum.2013.185","article-title":"Ocular inflammatory diseases associated with rheumatoid arthritis","volume":"10","author":"Artifoni","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"2021110402580715800_keab093-B2","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0161-6420(84)34160-4","article-title":"Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression","volume":"91","author":"Foster","year":"1984","journal-title":"Ophthalmology"},{"key":"2021110402580715800_keab093-B3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrd.2018.45","article-title":"Interleukin-6: designing specific therapeutics for a complex cytokine","volume":"17","author":"Garbers","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"2021110402580715800_keab093-B4","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","article-title":"Tocilizumab: a review in rheumatoid arthritis","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"2021110402580715800_keab093-B5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12348-019-0182-y","article-title":"Interleukin-6 inhibition in the management of non-infectious uveitis and beyond","volume":"9","author":"Karkhur","year":"2019","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"2021110402580715800_keab093-B6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/09273948.2019.1617885","article-title":"Successful tocilizumab treatment for scleritis","volume":"28","author":"Poelman","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"2021110402580715800_keab093-B7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jbspin.2017.01.002","article-title":"Incidence of paradoxical reactions in patients treated with tocilizumab for rheumatoid arthritis: data from the French registry REGATE","volume":"85","author":"Terreaux","year":"2018","journal-title":"Joint Bone Spine"},{"key":"2021110402580715800_keab093-B8","doi-asserted-by":"crossref","first-page":"e000239","DOI":"10.1136\/rmdopen-2015-000239","article-title":"Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview","volume":"2","author":"Toussirot","year":"2016","journal-title":"RMD Open"},{"key":"2021110402580715800_keab093-B9","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3899\/jrheum.170234","article-title":"Paradoxical nodular scleritis during tocilizumab therapy: a case report","volume":"44","author":"Michael","year":"2017","journal-title":"J Rheumatol"},{"key":"2021110402580715800_keab093-B10","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.3899\/jrheum.110170","article-title":"Onset of inflammatory eye disease under tocilizumab treatment for rheumatologic conditions: a paradoxical effect?","volume":"38","author":"Wendling","year":"2011","journal-title":"J Rheumatol"},{"key":"2021110402580715800_keab093-B11","first-page":"917","article-title":"Aqueous humor interleukin-6 levels in uveitis","volume":"31","author":"Murray","year":"1990","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2021110402580715800_keab093-B12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/03009742.2017.1376107","article-title":"Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials","volume":"47","author":"Brahe","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"2021110402580715800_keab093-B13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.exer.2014.06.012","article-title":"IL-6 as a corneal wound healing mediator in an in vitro scratch assay","volume":"125","author":"Arranz-Valsero","year":"2014","journal-title":"Exp Eye Res"},{"key":"2021110402580715800_keab093-B14","doi-asserted-by":"crossref","first-page":"8549","DOI":"10.1167\/iovs.11-7956","article-title":"Role of the IL-6 classic- and trans-signaling pathways in corneal sterile inflammation and wound healing","volume":"52","author":"Ebihara","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2021110402580715800_keab093-B15","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s00508-013-0460-x","article-title":"Does tocilizumab contribute to elevation of rheumatoid factor and induction of paradoxical syaloadenitis in rheumatoid arthritis patients?","volume":"126","author":"Martinovic Kaliterna","year":"2014","journal-title":"Wien Klin Wochenschr"},{"key":"2021110402580715800_keab093-B16","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/annrheumdis-2016-210297","article-title":"Low immunogenicity of tocilizumab in patients with rheumatoid arthritis","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021110402580715800_keab093-B17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/aos.13436","article-title":"Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting","volume":"96","author":"Baudouin","year":"2018","journal-title":"Acta Ophthalmol"},{"key":"2021110402580715800_keab093-B18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/acr.20689","article-title":"Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: results from the AutoImmunity and Rituximab Registry","volume":"64","author":"Pu\u00e9chal","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2021110402580715800_keab093-B19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/rheumatology\/kep390","article-title":"A case of bilateral peripheral ulcerative keratitis following treatment with rituximab","volume":"49","author":"Goodisson","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2021110402580715800_keab093-B20","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.semarthrit.2020.03.023","article-title":"Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients","volume":"50","author":"Dominguez-Casas","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2021110402580715800_keab093-B21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.survophthal.2018.06.002","article-title":"Surgical management of peripheral corneal thinning disorders","volume":"64","author":"Lohchab","year":"2019","journal-title":"Surv Ophthalmol"},{"key":"2021110402580715800_keab093-B22","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/ard.55.3.190","article-title":"Factors associated with the development of vasculitis in rheumatoid arthritis: results of a case-control study","volume":"55","author":"Voskuyl","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"2021110402580715800_keab093-B23","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/1753425917707026","article-title":"Sex differences in the pro-inflammatory cytokine response to endotoxin unfold in vivo but not ex vivo in healthy humans","volume":"23","author":"Wegner","year":"2017","journal-title":"Innate Immun"},{"key":"2021110402580715800_keab093-B24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/acr2.11101","article-title":"Predicting remission among patients with rheumatoid arthritis starting tocilizumab monotherapy: model derivation and remission score development","volume":"2","author":"Collins","year":"2020","journal-title":"ACR Open Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab093\/36622310\/keab093.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/11\/5413\/41073325\/keab093.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/11\/5413\/41073325\/keab093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T03:01:22Z","timestamp":1635994882000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/11\/5413\/6126360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,2]]},"references-count":24,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,2,2]]},"published-print":{"date-parts":[[2021,11,3]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab093","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,2,2]]}}}